Frequently Asked Questions (FAQs)
ORMALVITM (dichlorphenamide) tablets
ORMALVI is indicated for the treatment of hyperkalemic periodic paralysis, hypokalemic periodic paralysis and related variants.1 It is a carbonic anhydrase inhibitor, however the precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with Primary Periodic Paralysis is unknown.1
ORMALVI is the same proven dichlorphenamide as KEVEYIS*,2 accompanied by Cycle VitaTM, a dedicated support platform which, if you are eligible,** may help you live with confidence in managing your condition.
If you are interested in enrolling in ORMALVI (dichlorphenamide) tablets, you can download an enrollment form and share it with your doctor to discuss why you think ORMALVI may be suited to your needs.
ORMALVI is the same proven dichlorphenamide, accompanied by Cycle Vita, a dedicated support platform which, if you are eligible,** may help you live with confidence in managing your condition.
If you are interested in enrolling in ORMALVI (dichlorphenamide) tablets, you can download an enrollment form and share it with your doctor to discuss why you think ORMALVI may be suited to your needs.
Primary Periodic Paralysis diagnosis
Speak to your doctor about having a genetic test. A genetic is recommended as the first diagnostic step where there is a high clinical likelihood that you will be diagnosed with Primary Periodic Paralysis.2
If your genetic test comes back negative, one or more of the following tests could be utilized to help reach a diagnosis or rule out Primary Periodic Paralysis:
Electrocardiogram (ECG/EKG)
Electromyography (EMG)
Compound muscle action potential (CMAP)
Only 60% to 70% of patients with Primary Periodic Paralysis receive a positive genetic test.2
For the remaining 30% to 40% of patients with Primary Periodic Paralysis, diagnosis can be based upon clinical presentation, potassium levels in your blood during attacks, and pattern abnormalities on long exercise testing.2
Living with Primary Periodic Paralysis
Each type of Primary Periodic Paralysis has its own triggers and things you should avoid. Overall, strenuous activity, stress and extreme temperatures are triggers for all types of Primary Periodic Paralysis.3
Everyone is different, but patients with Primary Periodic Paralysis have reported that their condition has negative impacts on:
Work (68.3 %)
Overall physical health (59.8 %)
School (57.3 %)
Family life (37.8 %)
Overall mental health (30.5 %)
Relationships (25.6 %)4
With ORMALVI, you are not alone as Cycle Vita, our dedicated hub support program, delivers product support** at every step.
Patient support
Cycle Vita is our dedicated hub support program, which delivers product support** at every step.
The Cycle Vita team are just a phone call away. You can expect to hear from two types of people at Cycle Vita:
Access Specialists – help you access ORMALVI with enrollment, financial and pharmacy support**
Clinical Specialists – provide clinical education, clinical support and medication administration support**
+1 (888) 360-8482 hello@cyclevita.life www.cyclevita.life
When you are prescribed ORMALVI you can expect financial, logistics and educational support, including:
Bridge Program**: A free supply of ORMALVI that allows diagnosed patients to begin therapy immediately while Cycle Vita secures appropriate Benefit Verification and Prior Authorization. The Bridge Program may also be requested if you are an existing patient who is temporarily experiencing disruption in therapy due to insurance coverage.
Co-pay Program**: If you are commercially insured and eligible you may pay as little as $0.
Continuous Clinical Product Support: Cycle Vita provides you with product support to help manage every aspect of the ORMALVI therapeutic routine, such as clinical education and onboarding onto dichlorphenamide.
Patient Nutrition Program**: On-going personal guidance and education for patients through the duration of therapy tailored to the patient’s type of PPP and any known triggers, to reinforce their clinic’s nutrition plan**.
Patient Community Support: Finally reaching a diagnosis can be a relieving experience for patients, but it can be a challenging time too. Through Cycle Vita, we can introduce you to the Periodic Paralysis Association (PPA), a non-profit charitable corporation founded to foster awareness of periodic paralysis, promote science-based information regarding this class of disorder, and champion the interests of the Periodic Paralysis Community.
Finance and insurance
If you are a commercially insured eligible patient who has been prescribed ORMALVI, you may pay as little as $0 in co-pay**. To find out more about eligibility criteria please contact Cycle Vita on +1 (888) 360-8482.
If you are eligible, Cycle Vita will provide you with temporary free goods while your insurance coverage is being determined, through the Bridge Program.**
Through Cycle Vita, eligible** patients prescribed ORMALVI will have access to the Bridge Program, which provides a free supply of ORMALVI to diagnosed patients to allow you to begin therapy immediately while Cycle Vita secures appropriate Benefit Verification and Prior Authorization. The Bridge Program may also be requested if you are an existing patient who is temporarily experiencing disruption in therapy due to insurance coverage.
+1 (888) 360-8482
References
- ORMALVI (dichlorphenamide). Prescribing Information. Cycle Pharmaceuticals Ltd.
- Statland, J., et al (2017). Review of the Diagnosis and Treatment of Periodic Paralysis. Muscle & Nerve, [online] 57(4), pp.522–530. Available at:: https://doi.org/10.1002/mus.26009 [Accessed 1 Nov. 2023].
- www.youtube.com. (2023). 2023 PPA Conference: Anita Dharwadkar: Periodic Paralysis and Nutrition 005. [online] Available at: https://youtu.be/X6RWMp9sTJY [Accessed 30 Oct. 2023].
- Charles, B., et al (2013). Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. Journal of Neurology, [online] 260(10), pp.2606–2613. Available at: https://doi.org/10.1007/s00415-013-7025-9 [Accessed 1 Nov. 2023].
*KEVEYIS® and its associated logo is a trademark owned by or licensed to Xeris Pharmaceuticals, Inc.
**Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.